- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Methotrexate Matches Prednisone in Pulmonary Sarcoidosis Treatment Efficacy: Study

A new randomized trial, PREDMETH, has found that methotrexate is as effective as prednisone in improving lung function in treatment-naive patients with pulmonary sarcoidosis, and may offer a more tolerable side effect profile. Prednisone remains the first-line treatment, but its long-term side effects-such as weight gain, insomnia, and cushingoid appearance—often impact patient quality of life. Methotrexate, a potential alternative, had not previously been tested as a first-line option.
The PREDMETH trial, conducted across 17 hospitals in the Netherlands, randomized 138 patients (70 to prednisone, 68 to methotrexate) and assessed treatment over 24 weeks. The main outcome was change in forced vital capacity (FVC%), a key measure of lung function. Results showed no significant difference in FVC% change between the two groups at 24 weeks.
The adjusted between-group difference was -1.8% (90% CI -4.40 to 0.76), meeting the threshold for non-inferiority. Medication adherence was high in both arms—83% in the prednisone group, 81% in the methotrexate group. While the total number of adverse events (AEs) was similar across both groups, fewer AEs were still ongoing at 24 weeks in the methotrexate group (104 vs 171). Prednisone’s common side effects included increased weight, appetite, insomnia, and steroid-related appearance changes.
Methotrexate was associated more with nausea, fatigue, mild liver changes, and infections. This is the first trial to show that methotrexate may be a viable first-line option for pulmonary sarcoidosis. The distinct AE profiles highlight the importance of involving patients in choosing between therapies based on tolerance and lifestyle impact.
Reference:
V. Kahlmann, M. Veltkamp, C.C. Moor, M. Janssen Bonás, R.L.M. Mostard, H.N.A.J. van Rijswijk, J. van der Maten, E. Marges, L. Moonen, M. Overbeek, B. Koopman, M.J.J.H. Grootenboers, E.J. Nossent, M. Wagenaar, H. Kramer, P.L.M.L. Wielders, P. Bonta, S. Walen, B.A.H.A. Bogaarts, R. Kerstens, M. Overgaauw, J.C. Grutters, and M.S. Wijsenbeek. Methotrexate Versus Prednisone as First-line Treatment for Pulmonary Sarcoidosis: The PREDMETH Trial [abstract]. Am J Respir Crit Care Med 2025;211:A1007. https://doi.org/10.1164/ajrccm.2025.211.Abstracts.A1007
Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751